Skip to main content
Industry News
Drug combo boosts EFS in higher-risk myelodysplastic syndrome

People with higher-risk myelodysplastic syndrome who received pevonedistat and azacitidine had improved event-free survival and a trend toward overall survival improvement, compared with those who were given azacitidine alone, researchers reported at the virtual annual meeting of the Society of Hematologic Oncology. The findings also showed that those who received the drug combo had a 79% overall response rate, compared with 57% ORR among those in the azacitidine only group.

Full Story: